Date
|
Event
|
| April 2010 |
AACR 101st Annual Meeting 2010 |
|
Dr. Stefan Hart, Senior Scientist with S*BIO, will present a poster “SB1518, a novel oral JAK2-FLT3 inhibitor, is efficacious in models of acute myeloid leukemia and primary leukemic cells from patients” during the poster session at AACR 101st Annual Meeting 2010 in Washington, DC, 17-21 April 2010.
|
|
Session:
Venue:
Room:
Poster ID:
|
19 Apr 2010, 14:00-17:00pm
Walter E. Washington Convention Center
Exhibit Hall A-C, Section 22
2524
|
|
| March 2010 |
Drug Discovery Technology World Asia 2010 Conference at BioPharm Asia Convention 2010, Singapore |
|
Dr. Brian Dymock, S*BIO’s Head of Chemistry, will speak on “Impacting Medicinal Chemistry in the hottest areas in cancer: a perspective from Singaporean Biotech” in the session “Technologies in lead discovery and optimization” of the Drug Discovery Technology World Asia 2010 conference. This conference is part of the BioPharm Asia Convention 2010 held at the Raffles Convention Centre, Singapore, 16-19 March 2010.
|
|
Session:
Venue:
|
17 Mar 2009, 17:00-17:30pm
Raffles City Convention Centre, Singapore
|
|
| January 2010 |
UK-Singapore Symposium on Medicinal Chemistry |
|
Dr. Brian Dymock, S*BIO’s Head of Chemistry, will speak on ‘How to make real drugs the Singapore way: fast, furious and fun.’ This event will be held at the Matrix, Biopolis, Singapore from 25-26 January 2010.
|
|
Session:
Venue:
Room:
|
25 Jan 2010, 10:00-10:40am
Matrix, Biopolis, Singapore
Creation Theatrette, Level 4
|
|
|
Dr. P.M. Ramanujulu, Senior Scientist, and Dr. Stéphanie Blanchard, Medicinal Chemistry Scientist of S*BIO, will respectively present the posters ‘Novel inhibitors of PDK1 identified through NMR fragment based screening’ and ‘Purine derivatives as inhibitors of PDK-1’ at the UK-Singapore Symposium on Medicinal Chemistry.
|
|
Session:
Venue:
|
25 Jan 2010
Matrix, Biopolis, Singapore
|
|
| January 2010 |
Biotech Showcase 2010 |
|
Dr. Kantharaj Ethirajulu, S*BIO’s Head of Pre-Clinical Development will present at Biotech Showcase 2010. The presentation will highlight the significant progress made in the company’s clinical programs. The event is held in San Francisco from 12-13 January 2010.
|
|
Session:
Venue:
Room:
|
13 Jan 2010, 10:40-11:00am
Marines’ Memorial Club & Hotel, San Francisco, USA
Regimental Room, 10th Floor
|
|
| December 2009 |
2009 Annual Meeting of the American Society of Hematology in New Orleans, LA, USA |
|
Dr. Kee Chuan Goh, Senior Scientist with S*BIO, will present two posters on SB1518 at the conference.
|
|
Session Name:
Session:
Venue:
Room:
Poster ID:
Poster Title:
|
Myeloproliferative Syndromes I
5 Dec 2009, 5:30-7:30pm
Ernest N. Morial Convention Center
Hall E
I-910
Pharmacodynamic (PD) Biomarker Assay Validation for SB1518
|
Session Name:
Session:
Venue:
Room:
Poster ID:
Poster Title:
|
Myeloproliferative Syndromes Poster II
6 Dec 2009, 6:00-8:00pm
Ernest N. Morial Convention Center
Hall E
II-889
The Effects of SB1518 on ex vivo expanded PV Erythroid Progenitors
|
|
|
Dr. Anas Younes (University of Texas, MD Anderson Cancer Center) will give an oral presentation entitled "Phase I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma" at the conference.
|
|
Session Name:
Pre-Clinical Models:
Session:
Venue:
Room:
|
Lymphoma: Therapy with Biological Agents, excluding
New Targets in the Treatment of Lymphomas
7 Dec 2009, 4:00pm
Ernest N. Morial Convention Center
R02-R05
|
|
|
Dr. Srdan Verstovsek (University of Texas, MD Anderson Cancer Center) will present a poster on "Phase I Dose-Escalation Trial of SB1518" at the conference’s Myeloproliferative Syndromes session.
|
|
Session Name:
Session:
Venue:
Room:
Poster ID:
|
Myeloproliferative Syndromes Poster III
7 Dec 2009, 6:00-8:00pm
Ernest N. Morial Convention Center
Hall E
III-841
|
|
| November 2009 |
2009 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston, MA, USA |
|
Dr. Stefan Hart, Senior Scientist with S*BIO, will present a poster on our dual PI3K/mTOR program during the Poster Session of the 2009 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston, MA, USA, 15-19 November 2009.
|
|
Session:
Venue:
Room:
Poster ID:
|
17 Nov 2009, 12:30–2.30pm, Poster Session B
Hynes Convention Center
Halls C-D, 2nd Floor
B-138
|
|
|
Dr. Lilian Siu (Princess Margaret Hospital, Toronto, Canada) will present a clinical poster entitled “Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of SB939, an Oral Histone Deacetylase Inhbitor (HDACi), in Patients with Advanced Solid Tumors” during the Poster Session of the 2009 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston, MA, USA, 15-19 November 2009.
|
|
Session:
Venue:
Room:
Poster ID:
|
16 Nov 2009, 12:30–2.30pm, Poster Session B
Hynes Convention Center
Halls C-D, 2nd Floor
A185
|
|
| November 2009 |
CHI’s Seventh International Discovery on Target |
|
Dr. Haishan Wang, Group Leader of S*BIO, presented “Discovery of SB939, an HDAC Inhibitor with Class-Leading Properties” at CHI's Seventh International Discovery on Target held in Boston, US from 2-4 November 2009.
|
| October 2009 |
BIT’s Annual Congress of International Drug Discovery Science and Technology (IDDST) |
|
Dr. Anders Poulsen, Senior Scientist of S*BIO, presented “Structure-based Design of Aurora A&B Inhibitors” at BIT’s 7th Annual Congress of International Drug Discovery Science and Technology (IDDST) held in Shanghai, China from 22-25 October 2009
|
| October 2009 |
The Fourth Annual JMP Securities Healthcare Focus Conference |
|
Dr. Jan-Anders Karlsson, CEO of S*BIO presented and highlighted the significant progress made in S*BIO’s clinical programs at the Fourth Annual JMP Securities Healthcare Focus Conference. The event was held in New York from 5-6 October 2009.
|
| September 2009 |
World Pharma Trials Asia 2009 |
|
Dr. Joy Zhu, Senior Vice President, Global Clinical Development of S*BIO, presented “Leveraging on S*BIO geographical advantage in expanding clinical development in Asia” at the World Pharma Trials Asia 2009. This event was held in Shanghai, China from 23-25 September 2009.
|
| September 2009 |
Thomas Weisel Partners Group Healthcare Conference |
|
Dr. Jan-Anders Karlsson, CEO of S*BIO presented and highlighted the significant progress made in S*BIO’s clinical programs at the Thomas Weisel Partners Group Healthcare Conference 2009. The event was held in Boston from 9-11 September 2009.
|
| September 2009 |
Rodman & Renshaw 11th Annual Healthcare Conference |
|
Dr. Jan-Anders Karlsson, CEO of S*BIO presented at the Rodman & Renshaw 11th Annual Healthcare Conference. The presentation highlighted the significant progress made in S*BIO’s clinical programs. The event was held in New York from 9-11 September 2009.
|
| August 2009 |
International Symposium on Advances in Synthetic and Medicinal Chemistry |
|
Dr. Angeline Lee, Medicinal Chemistry Scientist of S*BIO, presented a poster at the 3rd International Symposium on Advances in Synthetic and Medicinal Chemistry held in Kiev, Ukraine from 23-27 August 2009. Her presentation entitled “Design and Synthesis of Novel Pyrimidine Macrocycles as Potent FLT3/JAK2 Inhibitor” was awarded the MedChemComm poster Prize at the conference.
|
| July 2009 |
International Conference on Medicinal Chemistry (RICT45) |
|
Dr. Stéphanie Blanchard, Scientist, Medicinal Chemistry, of S*BIO, presented at the 45th edition of the International Conference on Medicinal Chemistry (RICT 45). Her presentation at the Drug Discovery and Selection session was entitled ‘Targeted Small Molecule Anti-Cancer Drugs: An Asian Perspective from Discovery to Clinical’.
|
| June 2009 |
ChinaBio® Partnering Forum 2009 |
|
Dr. Stephen Rhind, Senior Vice President, Corporate Development, of S*BIO, presented at the ChinaBio® Partnering Forum 2009 where he highlighted the significant progress made in the company’s HDAC program.
|
| June 2009 |
2009 BIT Life Sciences' Annual World Cancer Congress |
|
Dr. Eric T Sun, Senior Scientific Advisor of S*BIO, presented at the BIT Life Sciences' Annual World Cancer Congress 2009. His presentation on ‘Potent and Orally-active HDAC Inhibitor’ was delivered in a session on ‘Rational Drug Design vs High Throughput Cancer Drug Screening’
|
|
Dr. Joy Zhu, Senior Vice President, Global Clinical Development, of S*BIO, chaired a session on ‘Molecular Therapeutics of Cancer ’ at the BIT Life Sciences' Annual World Cancer Congress 2009. In addition, she made an oral presentation entitled ‘Phase 1 Study of SB939, an Oral HDAC Inhibitor, in Patients with Advanced Solid Malignancies’.
|
| May 2009 |
2009 ASCO Annual Meeting |
|
Dr. Wei Peng Yong (National University Cancer Institute), presented a clinical poster on SB939, S*BIO’s HDAC Inhibitor during the 2009 ASCO Annual Meeting held in Orlando from 29 May to 2 June 2009.
Poster Title: Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies.
|
| May 2009 |
2009 BIO International Convention |
|
Dr. Joy Zhu, Senior Vice President, Global Clinical Development, of S*BIO, participated in a breakout session on ‘An Asia-First Strategy for Clinical Development of Therapeutic Drugs’ at the 2009 BIO International Convention.
|
| Apr 2009 |
AACR 100th Annual Meeting 2009 |
|
S*BIO presented two posters at the 100th AACR Annual Meeting in Colorado Convention Centre, Denver, Colorado, USA.
|
| Mar 2009 |
BioMedical Asia 2009 |
|
Dr Jan-Anders Karlsson, CEO of S*BIO, took part in a panel discussion on ‘How emerging companies from Asian biotech hubs can effectively tap into available funding opportunities’ at the BioMedical Asia 2009 conference in Singapore.
|
Home
